ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Effect of Perioperative Sivelstat Administration for Liver Resection (KMS)

This study has been completed.

Sponsored by: Kochi University
Information provided by: Kochi University
ClinicalTrials.gov Identifier: NCT00738348
  Purpose

It is reported that sivelstat improved and preserved the postoperative renal function in the orthopedic management. Moreover because sivelstat reduced the migration of neutrophil, it improved acute lung injury. During liver resection, Pringle maneuver, clamping the hepatoduodenal ligament, was performed. Pringle maneuver causes reperfusion injury of the liver. We have a hypothesis that sivelstat prevent the warm shock of reperfusion injury of the liver by Pringle maneuver.


Condition Intervention
Liver Diseases
Drug: sivelstat
Drug: glucose

MedlinePlus related topics:   Liver Diseases   

ChemIDplus related topics:   Dextrose   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study
Official Title:   Effect of Perioperative Sivelstat Administration for Liver Resection

Further study details as provided by Kochi University:

Primary Outcome Measures:
  • The incidence of liver damage due to reperfusion injury by Pringle maneuver was measured by several cytokines, including IL-8, IL-6, and HMGB-1. [ Time Frame: during hospitalization ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The duration of ICU stay and hospital stay, postoperative complications, and the liver damage at 6 POD, measuring hepato-biliary enzyme [ Time Frame: during hospitalization ] [ Designated as safety issue: Yes ]

Enrollment:   50
Study Start Date:   April 2007
Study Completion Date:   July 2008
Primary Completion Date:   May 2008 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
2: Active Comparator
250mL of 5% glucose plus 300mg of sivelstat was infected through the vein at 10mL per an hour
Drug: sivelstat
sivelstat sodiumhydrate
1: Placebo Comparator
250mL of 5% glucose was injected though the vein at 10mL per an hour
Drug: glucose
glucose

Detailed Description:

Whether the incidence of postoperative morbidities, such as liver failure, renal failure, or congestive heart failure, was reduced by administration of perioperative sivelstat.

  Eligibility
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

  • liver disease which surgical management was indicated

Exclusion Criteria:

  • weight loss greater than 10 per cent during the previous 6 months, signs of distant metastasis, or of respiratory, renal or heart disease
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00738348

Locations
Japan
Kochi Medical School    
      Kohasu-Okocho, Nankoku, Japan, 783-8505

Sponsors and Collaborators
Kochi University

Investigators
Study Director:     Takehiro Okabayashi, MD, PhD     Kochi Medical School    
  More Information


Responsible Party:   Kochi University ( Kochi Medical School )
Study ID Numbers:   ESAR, Kochi University
First Received:   August 18, 2008
Last Updated:   August 19, 2008
ClinicalTrials.gov Identifier:   NCT00738348
Health Authority:   Japan: Ministry of Education, Culture, Sports, Science and Technology

Keywords provided by Kochi University:
surgery  

Study placed in the following topic categories:
Liver Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on October 15, 2008




Links to all studies - primarily for crawlers